aTyr Pharma, Inc. (ATYR) vs Kyntra Bio, Inc. (KYNB)
A side-by-side comparison of aTyr Pharma, Inc. and Kyntra Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATYR
aTyr Pharma, Inc.
$0.29HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
KYNB
Kyntra Bio, Inc.
$5.99HealthcareDelayed quote: Oct 6, 2026, 11:22 AM EDT
Total return — ATYR vs KYNB
growth of $100 · dividends reinvested · last 2yATYR -83.2% (-59.1%/yr)KYNB -79.7% (-54.9%/yr)KYNB compounded faster over this window
ATYR KYNB
ATYR vs KYNB: by the numbers
- •ATYR is the larger company ($29M vs $24M market cap).
- •KYNB is profitable (3967.77% net margin) while ATYR runs a net loss (-32003.68%).
- •Both shrank revenue over the past five years; ATYR's decline was smaller (-38.74% vs -51.49% CAGR).
Metrics side by side
Valuation
| Metric | ATYR | KYNB |
|---|---|---|
| P/S ratio | 151.10 | 5.25 |
| P/B ratio | 0.59 | N/A |
Profitability
| Metric | ATYR | KYNB |
|---|---|---|
| Gross margin | -717.37% | 91.37% |
| Operating margin | -40856.32% | -712.66% |
| Net margin | -32003.68% | 3967.77% |
| ROE | -124.64% | N/A |
| ROIC | -109.29% | -78.16% |
Growth (annualized)
| Metric | ATYR | KYNB |
|---|---|---|
| Revenue CAGR (5Y) | -38.74% | -51.49% |
| Total return CAGR (5Y) | N/A | -52.67% |
Frequently asked
- Which has grown faster, ATYR or KYNB?
- Neither grew: over the past five years both shrank revenue, with ATYR's decline the smaller — ATYR at a -38.74% CAGR versus KYNB at -51.49%.
- Is ATYR or KYNB more profitable?
- KYNB runs the higher net margin — ATYR at -32003.68% versus KYNB at 3967.77%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.